Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia

MeSH terms

• Antineoplastic Combined Chemotherapy Protocols / therapeutic use
• Asparaginase / administration & dosage
• Combined Modality Therapy
• Cytarabine / administration & dosage
• Dasatinib
• Daunorubicin / administration & dosage
• Granulocyte Colony-Stimulating Factor / therapeutic use
• Humans
• In Situ Hybridization, Fluorescence
• Male
• Methotrexate / administration & dosage
• Mitoxantrone / administration & dosage
• Neoplasm Proteins / analysis
• Neoplasm Proteins / antagonists & inhibitors*
• Neoplasm Proteins / genetics
• Neutropenia / chemically induced
• Neutropenia / drug therapy
• Oncogene Proteins, Fusion / analysis
• Oncogene Proteins, Fusion / antagonists & inhibitors*
• Oncogene Proteins, Fusion / genetics
• Peripheral Blood Stem Cell Transplantation
• Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / complications
• Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
• Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
• Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / enzymology
• Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics
• Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / surgery
• Prednisone / administration & dosage
• Pyrimidines / therapeutic use*
• Remission Induction
• Splenic Rupture / etiology
• Splenic Rupture / surgery
• Thiazoles / therapeutic use*
• Vincristine / administration & dosage
• Young Adult